Resumen de Anagrelida en la trombocitemia esencial: Eficacia, seguridad y lugar terapéutico
Mª J. Agustín Ferrández, Isabel Villar Fernández, Herminia Navarro Aznárez, A. Idoipe Tomás, M. C. Viñuales Armengol
This is a retrospective study, from 1998 to April 2002, about patients with essential thrombocythemia (ET) treated with anagrelide in a hospital. The purpose of this work is to develop a utilization study, by evaluating its efficacy and its safety. 24 patients were analyzed, among which 20 had undergone other treatments for ET previous to anagrelide. The adverse effects (tachycardia/palpitations, anemia, headaches and hydric retention) were light, temporary and led to less quitting. In patients that used anagrelide as a first line and in those who had failed in their previous treatment, the response was of 95.2%. Anagrelide is a good alternative for patients with ET in which the previous treatment with either a-interferon (INF) or hydroxyurea (HU) has failed, or even for those patients in which these treatments cannot be used. Given anagrelide's narrow therapeutic margin, it is necessary an individualized follow-up of the patient in order to attain the maintenance optimal dosage
